PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 7, 2001New England Journal of Medicine1,096 citations

The Hemophilias — From Royal Genes to Gene Therapy

View Full Paper
PMPier Mannuccio MannucciETEdward G. D. Tuddenham

Key Points

  • To review the genetic mechanisms, inheritance patterns, and therapeutic evolution associated with coagulation factor VIII and factor IX deficiencies in hemophilia.
  • Narrative synthesis of the molecular genetics underlying hemophilia A and hemophilia B.
  • Evaluation of X-linked inheritance, spontaneous mutation epidemiology, and modern translational gene therapy strategies.
  • Inherited deficiencies in factor VIII or factor IX result in hemophilia A and B, respectively, manifesting as X-linked recessive disorders predominantly affecting males.
  • Transmission typically occurs through maternal carrier inheritance, with approximately 30 percent of cases occurring due to de novo spontaneous mutations.

Abstract

Of the various types of hemophilia, the most common of these lifelong bleeding disorders are due to an inherited deficiency of factor VIII or factor IX (Table 1). The genes for these blood coagulation factors lie on the X chromosome, and when mutated, they cause the X-linked recessive traits hemophilia A and B. Since these disorders are X-linked, they usually occur in males. Usually, the affected boy has inherited the mutant gene (XH ) from his carrier mother (X H/X ), but about 30 percent of cases arise from a spontaneous mutation, and there is . . .

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mannucci et al. (2001) studied this question.

synapsesocial.com/papers/6a0ee7fb950456576347dde0https://doi.org/10.1056/nejm200106073442307
Ask AI
Helpful
Bookmark
Share
View Full Paper